RE:RE:RE:RE:of value to non TST bagholders and brought hereHmm, I'd imagine he means the following:
There is no such thing as a low priority 2L oncology filing (and lets face it, if approved this will be used off label 1L too - FDA will be aware of this)
So, the logic goes that if the filing will be accepted, this almost automatically will mean priority status too. Doesn't make standard review impossible, just the less likely option, given therapeutic setting.